Cargando…
A DUAL MTOR/NAD+ ACTING GEROTHERAPY
The geroscience hypothesis states that a therapy that prevents the underlying aging process should prevent multiple aging related diseases. The mTOR (mechanistic target of rapamycin)/insulin and NAD+ (nicotinamide adenine dinucleotide) pathways are two of the most validated aging pathways. Yet, it’s...
Autores principales: | Li, Jinmei, Kumar, Sandeep, Miachin, Kirill, Bean, Nicholas L., Halawi, Ornella, Lee, Scott, Park, JiWoong, Pierre, Tanya H., Hor, Jin-Hui, Ng, Shi-Yan, Wallace, Kelvin J., Rindtorff, Niklas, Miller, Timothy M., Niehoff, Michael L., Farr, Susan A., Kletzien, Rolf F., Colca, Jerry, Tanis, Steven P., Chen, Yana, Griffett, Kristine, McCommis, Kyle S., Finck, Brian N., Peterson, Tim R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882180/ https://www.ncbi.nlm.nih.gov/pubmed/36711589 http://dx.doi.org/10.1101/2023.01.16.523975 |
Ejemplares similares
-
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
por: Colca, Jerry R., et al.
Publicado: (2017) -
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
por: McCommis, Kyle S., et al.
Publicado: (2018) -
The Hepatic Mitochondrial Pyruvate Carrier as a Regulator of Systemic Metabolism and a Therapeutic Target for Treating Metabolic Disease
por: McCommis, Kyle S., et al.
Publicado: (2023) -
Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
por: Hodges, Wesley T., et al.
Publicado: (2021) -
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide
por: Kamm, Dakota R., et al.
Publicado: (2021)